oxybutynin has been researched along with Carcinoma, Transitional Cell in 1 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Johnson, MH | 1 |
| Nepple, KG | 1 |
| Peck, V | 1 |
| Trinkaus, K | 1 |
| Klim, A | 1 |
| Sandhu, GS | 1 |
| Kibel, AS | 1 |
1 trial available for oxybutynin and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Carcinoma, Transitional Cel | 2013 |